Furutani K
Int J Mol Sci. 2023; 24(22).
PMID: 38003453
PMC: 10671758.
DOI: 10.3390/ijms242216261.
Abdullah Y
Cureus. 2023; 15(10):e47501.
PMID: 37877107
PMC: 10591113.
DOI: 10.7759/cureus.47501.
Santini L, Duranti C, Palandri C, Giammarino L, Musumeci M, Carlucci L
Front Pharmacol. 2023; 14:1237431.
PMID: 37767396
PMC: 10520717.
DOI: 10.3389/fphar.2023.1237431.
Zheng Z, Song Y
BMC Bioinformatics. 2023; 24(1):51.
PMID: 36792990
PMC: 9933257.
DOI: 10.1186/s12859-023-05180-9.
Chioccioli Altadonna G, Montalbano A, Iorio J, Becchetti A, Arcangeli A, Duranti C
Membranes (Basel). 2022; 12(11).
PMID: 36422154
PMC: 9698864.
DOI: 10.3390/membranes12111162.
New Diarylamine K10.1 Inhibitors and Their Anticancer Potential.
Gubic S, Toplak Z, Shi X, Dernovsek J, Hendrickx L, Pinheiro-Junior E
Pharmaceutics. 2022; 14(9).
PMID: 36145712
PMC: 9501377.
DOI: 10.3390/pharmaceutics14091963.
Ion Channel Involvement in Tumor Drug Resistance.
Altamura C, Gavazzo P, Pusch M, Desaphy J
J Pers Med. 2022; 12(2).
PMID: 35207698
PMC: 8878471.
DOI: 10.3390/jpm12020210.
Non-cancer to anti-cancer: investigation of human ether-a-go-go-related gene potassium channel inhibitors as potential therapeutics.
Patil V, Gaurav A, Garg P, Masand N
J Egypt Natl Canc Inst. 2021; 33(1):33.
PMID: 34746987
DOI: 10.1186/s43046-021-00091-3.
Assessing hERG1 Blockade from Bayesian Machine-Learning-Optimized Site Identification by Ligand Competitive Saturation Simulations.
Mousaei M, Kudaibergenova M, MacKerell Jr A, Noskov S
J Chem Inf Model. 2020; 60(12):6489-6501.
PMID: 33196188
PMC: 7839320.
DOI: 10.1021/acs.jcim.0c01065.
Targeting Ion Channels for Cancer Treatment: Current Progress and Future Challenges.
Capatina A, Lagos D, Brackenbury W
Rev Physiol Biochem Pharmacol. 2020; 183:1-43.
PMID: 32865696
DOI: 10.1007/112_2020_46.
Ion Channel Dysregulation in Head and Neck Cancers: Perspectives for Clinical Application.
Del-Rio-Ibisate N, Granda-Diaz R, Rodrigo J, Menendez S, Garcia-Pedrero J
Rev Physiol Biochem Pharmacol. 2020; 181:375-427.
PMID: 32789787
DOI: 10.1007/112_2020_38.
hERG K Channels Promote Survival of Irradiated Leukemia Cells.
Palme D, Misovic M, Ganser K, Klumpp L, Salih H, Zips D
Front Pharmacol. 2020; 11:489.
PMID: 32390841
PMC: 7194033.
DOI: 10.3389/fphar.2020.00489.
Clarithromycin inhibits autophagy in colorectal cancer by regulating the hERG1 potassium channel interaction with PI3K.
Petroni G, Bagni G, Iorio J, Duranti C, Lottini T, Stefanini M
Cell Death Dis. 2020; 11(3):161.
PMID: 32123164
PMC: 7052256.
DOI: 10.1038/s41419-020-2349-8.
MicroRNA 362-3p Reduces hERG-related Current and Inhibits Breast Cancer Cells Proliferation.
Assiri A, Mourad N, Shao M, Kiel P, Liu W, Skaar T
Cancer Genomics Proteomics. 2019; 16(6):433-442.
PMID: 31659098
PMC: 6885367.
DOI: 10.21873/cgp.20147.
Identification of candidate genes for devil facial tumour disease tumourigenesis.
Taylor R, Zhang Y, Schoning J, Deakin J
Sci Rep. 2017; 7(1):8761.
PMID: 28821767
PMC: 5562891.
DOI: 10.1038/s41598-017-08908-9.
hERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy.
Muratori L, Petroni G, Antonuzzo L, Boni L, Iorio J, Lastraioli E
Onco Targets Ther. 2016; 9:6325-6332.
PMID: 27789963
PMC: 5072508.
DOI: 10.2147/OTT.S114090.
hERG1 potassium channel in cancer cells: a tool to reprogram immortality.
Gentile S
Eur Biophys J. 2016; 45(7):649-655.
PMID: 27649700
DOI: 10.1007/s00249-016-1169-3.
Gene Signature of High White Blood Cell Count in B-Precursor Acute Lymphoblastic Leukemia.
Edwards H, Rubenstein M, Dombkowski A, Caldwell J, Chu R, Xavier A
PLoS One. 2016; 11(8):e0161539.
PMID: 27536776
PMC: 4990277.
DOI: 10.1371/journal.pone.0161539.
Effects of Temperature on Heteromeric Kv11.1a/1b and Kv11.3 Channels.
Mauerhofer M, Bauer C
Biophys J. 2016; 111(3):504-523.
PMID: 27508435
PMC: 4982939.
DOI: 10.1016/j.bpj.2016.07.002.
Activation of hERG3 channel stimulates autophagy and promotes cellular senescence in melanoma.
Perez-Neut M, Haar L, Rao V, Santha S, Lansu K, Rana B
Oncotarget. 2016; 7(16):21991-2004.
PMID: 26942884
PMC: 5008339.
DOI: 10.18632/oncotarget.7831.